Search - tctmd.com

Displaying 61 - 80 of 178

Sort: Relevancy | Date

Presentation TCT 2017

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

Presenter: Robert O. Bonow, Michael J. Mack, Randolph P. Martin

October 30, 2017

Presentation TCT 2017

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

Presenter: Robert O. Bonow, Michael J. Mack, Maximilian Y Emmert

October 30, 2017

Presentation TCT 2017

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Presenter: Robert O. Bonow, Michael J. Mack, David Hildick-Smith

October 30, 2017

Presentation TCT 2017

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Presenter: Robert O. Bonow, Michael J. Mack, Maurice E. Sarano

October 30, 2017

Presentation TCT 2017

Counterpoint Access to Modern Valve Therapies for Underserved Populations Trumps Arbitrary Guidelines Favoring High-Volume Urban Centers!

Presenter: Uzoma Ibebuogu

October 30, 2017

Presentation TCT 2017

Point A Tiered Centers of Excellence Approach Makes Sense!

Presenter: Patrick T. O'Gara

October 30, 2017

Presentation TCT 2017

Counterpoint In the Modern Era, Crowd Wisdom, Cumulative Experience and New Technology Trumps Case Volume!

Presenter: Martin B. Leon

October 30, 2017

Presentation TCT 2017

Point - Clearly, The More You Do, The Better You Are!

Presenter: John D. Carroll

October 30, 2017

Presentation TCT 2017

Featured Lecture: The Vancouver Multidisciplinary, Multimodality, but Minimalist Clinical Pathway Facilitates Safe Next Day Discharge Home at Low, Medium, and High Volume Transcatheter Aortic Valve Replacement Centres: the 3M TAVR Study

Presenter: Robert O. Bonow, Michael J. Mack, David A. Wood

October 30, 2017

Presentation TCT 2017

Staging Classification of Aortic Stenosis Based Upon the Extent of Cardiac Damage A Novel Concept

Presenter: Robert O. Bonow, Michael J. Mack, Philippe Genereux

October 30, 2017

Presentation TCT 2017

Refining the Classic Definition of Aortic Stenosis: A Dynamic Interpretation Including the Role of Ventricular Stroke Work and Vascular Impedance

Presenter: Robert O. Bonow, Michael J. Mack, Elazer R. Edelman

October 30, 2017

Presentation TCT 2017

Slovakia Presents: Case Conclusion - How I Treated This Case

Presenter: Petr Kala, Jochen Wöhrle, Petra Poliacikova

October 30, 2017

Presentation TCT 2017

Germany Comments: How Would I Treat This Case and Why?

Presenter: Petr Kala, Jochen Wöhrle, Thomas Walther

October 30, 2017

Presentation TCT 2017

Slovakia Presents: Case Introduction - A Patient With Critical Coronary Disease and Severe Aortic Stenosis

Presenter: Petr Kala, Jochen Wöhrle, Petra Poliacikova

October 30, 2017

Presentation TCT 2017

Poland Presents: Case Conclusion - How I Treated This Case

Presenter: Petr Kala, Jochen Wöhrle, Dariusz Dudek

October 30, 2017

Presentation TCT 2017

Czech Republic Comments: How Would I Treat This Case and Why?

Presenter: Petr Kala, Jochen Wöhrle, Marian Branny

October 30, 2017

Presentation TCT 2017

Poland Presents: Case Introduction - A Patient With Critical Coronary Disease and Severe Aortic Stenosis

Presenter: Petr Kala, Jochen Wöhrle, Dariusz Dudek

October 30, 2017

Presentation TCT 2017

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

Presenter: Petr Kala, Jochen Wöhrle, Martin Hudec

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Allan Schwartz

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Presenter: David H. Adams, Ted Feldman, Vinod H. Thourani

October 30, 2017

Advertisement

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Counterpoint Access to Modern Valve Therapies for Underserved Populations Trumps Arbitrary Guidelines Favoring High-Volume Urban Centers!

Point A Tiered Centers of Excellence Approach Makes Sense!

Counterpoint In the Modern Era, Crowd Wisdom, Cumulative Experience and New Technology Trumps Case Volume!

Point - Clearly, The More You Do, The Better You Are!

Featured Lecture: The Vancouver Multidisciplinary, Multimodality, but Minimalist Clinical Pathway Facilitates Safe Next Day Discharge Home at Low, Medium, and High Volume Transcatheter Aortic Valve Replacement Centres: the 3M TAVR Study

Staging Classification of Aortic Stenosis Based Upon the Extent of Cardiac Damage A Novel Concept

Refining the Classic Definition of Aortic Stenosis: A Dynamic Interpretation Including the Role of Ventricular Stroke Work and Vascular Impedance

Slovakia Presents: Case Conclusion - How I Treated This Case

Germany Comments: How Would I Treat This Case and Why?

Slovakia Presents: Case Introduction - A Patient With Critical Coronary Disease and Severe Aortic Stenosis

Poland Presents: Case Conclusion - How I Treated This Case

Czech Republic Comments: How Would I Treat This Case and Why?

Poland Presents: Case Introduction - A Patient With Critical Coronary Disease and Severe Aortic Stenosis

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content